Enhancing skin permeation of biphenylacetic acid (BPA) using salt formation with organic and alkali metal bases

Scientia Pharmaceutica

Volumn 83, Issue 1, 2015, Pages 191-205

  Pawar, Vijay ^a   Naik, Prashant ^a   Giridhar, Rajani ^a   Yadav, Mange Ram ^a  

^a M S UNIVERSITY OF BARODA   (India)

Author keywords

BPA; Lipophilicity; NSAID; Salt; Skin permeation

Indexed keywords

ALKALI METAL BASE; FELBINAC; ORGANIC METAL BASE; PENETRATION ENHANCING AGENT; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DELIVERY SYSTEM; DRUG SCREENING; DRUG SOLUBILITY; DRUG SYNTHESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; INFRARED SPECTROSCOPY; MALE; MELTING POINT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PHYSICAL CHEMISTRY; RAT; SCANNING ELECTRON MICROSCOPY; SKIN PERMEABILITY; STEADY STATE;

EID: 84924251058     PISSN: 00368709     EISSN: 22180532     Source Type: Journal    
DOI: 10.3797/scipharm.1406-19     Document Type: Article

References (31)

1. Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors: Structures, properties, and functions. Physiol Rev. 1999; 79: 1193-1226. http://www.ncbi.nlm.nih.gov/pubmed/10508233
2. Johnson AG, Quinn DI, Day RO. Non-steroidal anti-inflammatory drugs. Med J Aust. 1995; 163: 155-158. http://www.ncbi.nlm.nih.gov/pubmed/7643770
3. Figueras A, Capellà D, Castel JM, Laorte JR. Spontaneous reporting of adverse drug reactions to non-stroidal anti-inflammatory drugs. A report from the spanish system of pharmacovigilance, including an early analysis of topical and enteric coated formulations. Eur J Clin Pharmacol. 1994; 47: 297-303. http://dx.doi.org/10.1007/BF00191158
4. Lichtenstein DR, Syngal S, Wolfe MM. Nonsteroidal anti-inflammatory drugs and the gastrointestinal tract. The double edged sword. Arthritis Rheum. 1995; 38: 5-18. http://dx.doi.org/10.1002/art.1780380103
5. Hansen TM, Matzen P, Madsen P. Endoscopic evaluation of the effect of indomethacin capsules and suppositories on the gastric mucosa in rheumatic patients. J Rheumatol. 1984; 11: 484-487. http://www.ncbi.nlm.nih.gov/pubmed/6332910
6. Lee CM, Maibach HI. Deep percutaneous penetration into muscles and joints. J Pharm Sci. 2006; 95: 1405-1413. http://dx.doi.org/10.1002/jps.20666
7. Mason L, Moore RA, Edwards JE, Derry S, McQuay HJ. Topical NSAIDs for chronic musculoskeletal pain: systematic review and meta analysis. BMC Musculoskelet Disord. 2004; 5: 28-38. http://dx.doi.org/10.1186/1471-2474-5-28
8. Altman RD. New guidelines for topical NSAIDs in the osteoarthritis treatment paradigm. Curr Med Res Opin. 2010; 26: 2871-2876. http://dx.doi.org/10.1185/03007995.2010.533650
9. Singh P. In: Percutaneous penetration as a method of delivery to skin and underlying tissues. Bronaugh RL, Maibach HI. New York: Marcel Dekker Inc, 1999: 597-613. http://dx.doi.org/10.3109/9780203904015-23
10. Roberts MS, Cross SE. Percutaneous absorption of topically applied NSAIDs and other compounds: role of solute properties, skin physiology and delivery system. Inflammopharmacology. 1999; 7: 339-350. http://dx.doi.org/10.1007/s10787-999-0028-6
11. Rautio J, Nevalainen T, Taipale H, Vepsäläinen J, Gynther J, Laine K, Järvinen T. Piperazinyl alkyl prodrugs of naproxen improve in vitro skin permeation. Eur J Pharm Sci. 2000; 11: 157-163. http://dx.doi.org/10.1016/S0928-0987(00)00090-7
12. Yanagimoto G, Hayashi T, Hasegawa T, Seki T, Juni K, Sugibayashi K, Morimoto Y. Skin disposition of drug after topical application in hairless rats. Chem Pharm Bull. 1999; 47: 749-754. http://dx.doi.org/10.1248/cpb.47.749
13. El-Menshawe SF, Hussein AK. Formulation and evaluation of meloxicam niosomes as vesicular carriers for enhanced skin delivery. Pharm Dev Technol. 2013; 18: 779-786. http://dx.doi.org/10.3109/10837450.2011.598166
14. Israel B, Garner ST, Thakare M, Elder D, Abney T, Azadi P, Beach JW, Price JC, Ahmed H, Capomacchia AC. Transdermal permeation of novel n-acetyl-glucosamine/NSAIDs mutual prodrugs. Pharm Dev Technol. 2012; 17: 48-54. http://dx.doi.org/10.3109/10837450.2010.513987
15. Budai L, Kaszás N, Gróf P, Lenti K, Maghami K, Antal I, Klebovich I, Petrikovics I, Budai M. Liposomes for topical use: a physico-chemical comparison of vesicles prepared from egg or soy lecithin. Sci Pharm. 2013; 81: 1151-1166. http://dx.doi.org/10.3797/scipharm.1305-11
16. Barry BW. Mode of Action of Penetration Enhancers in Human Skin. J Controlled Rel. 1987; 6: 85-97. http://dx.doi.org/10.1016/0168-3659(87)90066-6
17. Gaur PK, Purohit S, Kumar Y, Mishra S, Bhandari A. Preparation, characterization and permeation studies of a nanovesicular system containing diclofenac for transdermal delivery. Pharm Dev Technol. 2014; 19: 48-54. http://dx.doi.org/10.3109/10837450.2012.751406
18. Kim BY, Doh HJ, Le TN, Cho WJ, Yong CS, Choi HG, Kim JS, Lee CH, Kim DD. Ketorolac amide prodrugs for transdermal delivery: Stability and in vitro rat skin permeation studies. Int J Pharm. 2005; 293: 193-202. http://dx.doi.org/10.1016/j.ijpharm.2005.01.002
19. Chan SY, Li WPA. Prodrugs for Dermal Delivery. Int J Pharm. 1989; 55: 1-16. http://dx.doi.org/10.1016/0378-5173(89)90270-6
20. Sloan KB. Prodrugs for Dermal Delivery. Adv Drug Del Rev. 1989; 3: 67-101 http://dx.doi.org/10.1016/0169-409X(89)90005-7
21. Roy SD, Manoukian E. Permeability of Ketorolac Acid and Its Ester Analogues (Prodrugs) Through Human Cadaver Skin. J Pharm Sci. 1994; 83: 1548-1553. http://dx.doi.org/10.1002/jps.2600831106
22. Fang L, Numajiri S, Kobayashi D, Ueda H, Nakayama K, Miyamae H, Morimoto Y. Physicochemical and crystallographic characterization of mefenamic acid complexes with alkanolamines. J Pharm Sci. 2004; 93: 144-154. http://dx.doi.org/10.1002/jps.10468
23. Cheong HA, Choi HK. Enhanced percutaneous absoption of piroxicam via salt formation with ethanolamines. Pharm Res. 2002; 19: 1375-1380. http://dx.doi.org/10.1023/A:1020367212307
24. Sloboda AE, Osterberg AC. The pharmacology of a fenbufen, 3-(4-biphenyl carbonyl)propionic acid and 4-biphenylacetic acid interesting anti-inflammatory-analgesic agents. Inflammation. 1976; 1: 415-438. http://dx.doi.org/10.1007/BF00920340
25. Dawson M, McGee CM, Vine JH, Nash P, Watson TR, Brooks PM. The disposition of biphenylacetic acid following topical application. Eur J Clin Pharmacol. 1988; 33: 639-642. http://dx.doi.org/10.1007/BF00542502
26. Hadgraft J, Du Plessis J, Goosen C. The selection of non-steroidal anti-inflammatory agents for dermal delivery. Int J Pharm. 2000; 207: 31-37. http://dx.doi.org/10.1016/S0378-5173(00)00517-2
27. Vaile JH, Davis P. Topical NSAIDs for musculoskeletal conditions. Drugs. 1998; 56: 783-799. http://dx.doi.org/10.2165/00003495-199856050-00004
28. Komatsu T, Sakurada T. Comparison of the efficacy and skin permeability of topical NSAID preparations used in Europe. Eur J Pharm Sci. 2012; 47: 890-895. http://dx.doi.org/10.1016/j.ejps.2012.08.016
29. Khan MS, Akhter M, Husain A. Synthesis, biological evaluation and kinetic studies of glyceride prodrugs of biphenyl acetic acid. Ind J Chem B. 2006; 45: 1014-1019.
30. Hadgraft J, Valenta C. pH, pKa and dermal delivery. Int J Pharm. 2000; 200: 243-247. http://dx.doi.org/10.1016/S0378-5173(00)00402-6
31. Schwenk E, Papa D. Preparation of aryl aliphatic acids by the modified willgerodt reaction. J Org Chem. 1946; 11: 798. http://dx.doi.org/10.1021/jo01176a023